scholarly journals Analysis of efficacy and safety of electroconvulsive therapy in elderly patients: a retrospective study in the Polish population

2021 ◽  
pp. 1-19
Author(s):  
Anna Antosik-Wójcińska ◽  
Monika Dominiak ◽  
Zuzanna Goetz ◽  
Adam Gędek ◽  
Anna Braniecka ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Elderly Patients ◽  
Electroconvulsive Therapy ◽  
Polish Population ◽  
Efficacy And Safety

Efficacy and Safety of Continuation and Maintenance Electroconvulsive Therapy in Depressed Elderly Patients: A Systematic Review

2012 ◽  
Vol 20 (1) ◽  
pp. 5-17 ◽  
Author(s):  
Audrey M. van Schaik ◽  
Hannie C. Comijs ◽  
Caroline M. Sonnenberg ◽  
Aartjan T. Beekman ◽  
Pascal Sienaert ◽  
...  
Keyword(s):  
Systematic Review ◽  
Elderly Patients ◽  
Electroconvulsive Therapy ◽  
Efficacy And Safety

Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study

2019 ◽  
Vol 94 ◽  
pp. 178-182 ◽  
Author(s):  
Chiara Del Bianco ◽  
Fabio Placidi ◽  
Claudio Liguori ◽  
Luisa Mari ◽  
Martina Ulivi ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Elderly Patients ◽  
Focal Epilepsy ◽  
Efficacy And Safety ◽  
Term Efficacy

Does psychosis predict response to ECT in depressed elderly patients?

1999 ◽  
Vol 16 (1) ◽  
pp. 13-15
Author(s):  
Niall Gormley ◽  
Con Cullen ◽  
Liam Watters ◽  
Michael Philpot ◽  
Brian A Lawlor
Keyword(s):  
Retrospective Study ◽  
Elderly Patients ◽  
Treatment Option ◽  
Electroconvulsive Therapy ◽  
Therapy Response ◽  
Psychiatric Hospitals ◽  
Depressive Illness ◽  
Response To Treatment ◽  
Depressed Patients

AbstractObjectives: To compare the electroconvulsive therapy response of a sample of depressed elderly patients as a function of the presence or absence of psychosis.Method: Retrospective study of patients over age 65 treated with ECT at three psychiatric hospitals over a three year period.Results: One hundred and eighty-nine ECT courses were administered to 135 patients. Almost 8 5% of patients made a marked or moderately good response to treatment. There was no difference in ECT response between psychotic and non-psychotic depressed patients.Conclusions: ECT should be considered as a treatment option for severe depressive illness, regardless of depressive subtype.

Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study

2020 ◽  
Vol 45 (7) ◽  
pp. 888-890 ◽  
Author(s):  
M. Napolitano ◽  
G. Fabbrocini ◽  
M. Scalvenzi ◽  
C. Blasio ◽  
L. Stingeni ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Retrospective Study ◽  
Elderly Patients ◽  
Efficacy And Safety

scholarly journals Efficacy and safety of brand-risperidone versus similar-risperidone in elderly patients with neuropsychiatric disorders: A retrospective study

2010 ◽  
Vol 4 (1) ◽  
pp. 69-74
Author(s):  
Jefferson Cunha Folquitto ◽  
Sérgio Barbosa de Barros ◽  
Jony Arrais Pinto Junior ◽  
Cássio M.C. Bottino
Keyword(s):  
Retrospective Study ◽  
Adverse Effects ◽  
Elderly Patients ◽  
Clinical Global Impression ◽  
Neuropsychiatric Disorders ◽  
Efficacy And Safety ◽  
Clinical Global Impression Scale ◽  
Elderly Outpatients ◽  
Significant Difference ◽  
Risperidone Group

Abstract To compare the efficacy and tolerability of brand-risperidone against similar-risperidone in elderly outpatients. Method: The medical files of 16 elderly outpatients from the IPq-HCFMUSP treated with two formulations of risperidone (brand and similar) between July/1999 and February/2000 were reviewed. Two independent raters, using the Clinical Global Impression scale, evaluated the efficacy of the treatment with risperidone and the frequency of adverse effects. Results: Comparing October/1999 to November/1999, Rater 1 observed a trend (p=0.059) and Rater 2 found a statistically significant difference, in favor of the brand-risperidone group (p=0.014). Comparing October/1999 to February/2000, Rater 1 observed no statistically significant difference (p=0.190), but the Rater 2 found a statistically significant difference in favor of the brand-risperidone group (p=0.029). Comparing November/1999 to February/2000, both raters found no statistically significant differences between both risperidone formulations. Regarding adverse effects, a statistically significant difference (p=0.046) was found in favor of the patients treated with brand-risperidone. Conclusions: The risperidone-reference, compared to similar-risperidone, showed a trend toward greater efficacy and tolerability.

Sign in / Sign up

Export Citation Format

Share Document